PortalPublikationenDoes increasing the nodal yield improve outcomes in contempo...

Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?

Standard

Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? / Kluth, Luis A; Xylinas, Evanguelos; Rieken, Malte; Chun, Felix K-H; Fajkovic, Harun; Becker, Andreas; Karakiewicz, Pierre I; Passoni, Niccolo; Herman, Michael; Lotan, Yair; Seitz, Christian; Schramek, Paul; Remzi, Mesut; Loidl, Wolfgang; Guillonneau, Bertrand; Rouprêt, Morgan; Briganti, Alberto; Scherr, Douglas S; Graefen, Markus; Tewari, Ashutosh K; Shariat, Shahrokh F.

in: UROL ONCOL-SEMIN ORI, Jahrgang 32, Nr. 1, 01.01.2014, S. 47.e1-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kluth, LA, Xylinas, E, Rieken, M, Chun, FK-H, Fajkovic, H, Becker, A, Karakiewicz, PI, Passoni, N, Herman, M, Lotan, Y, Seitz, C, Schramek, P, Remzi, M, Loidl, W, Guillonneau, B, Rouprêt, M, Briganti, A, Scherr, DS, Graefen, M, Tewari, AK & Shariat, SF 2014, 'Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?', UROL ONCOL-SEMIN ORI, Jg. 32, Nr. 1, S. 47.e1-8. https://doi.org/10.1016/j.urolonc.2013.06.013

APA

Kluth, L. A., Xylinas, E., Rieken, M., Chun, F. K-H., Fajkovic, H., Becker, A., Karakiewicz, P. I., Passoni, N., Herman, M., Lotan, Y., Seitz, C., Schramek, P., Remzi, M., Loidl, W., Guillonneau, B., Rouprêt, M., Briganti, A., Scherr, D. S., Graefen, M., ... Shariat, S. F. (2014). Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? UROL ONCOL-SEMIN ORI, 32(1), 47.e1-8. https://doi.org/10.1016/j.urolonc.2013.06.013

Vancouver

Kluth LA, Xylinas E, Rieken M, Chun FK-H, Fajkovic H, Becker A et al. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? UROL ONCOL-SEMIN ORI. 2014 Jan 1;32(1):47.e1-8. https://doi.org/10.1016/j.urolonc.2013.06.013

Bibtex

@article{4ae1c0cef47b4f15919f1f1ca23aa990,
title = "Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?",
abstract = "OBJECTIVES: To determine if the number of lymph nodes (LNs) removed is an independent predictor of biochemical recurrence (BCR) in patients without LN metastases undergoing radical prostatectomy (RP).MATERIAL AND METHODS: Retrospective analysis of 7,310 patients treated at 7 centers with RP and pelvic LN dissection for clinically localized prostate cancer between 2000 and 2011. Patients with LN metastases (n = 398) and other reasons (stated later in the article) (n = 372) were excluded, which left 6,540 patients for the final analyses.RESULTS: Overall, median biopsy and RP Gleason score were both 7; median prostate specific antigen level was 6 ng/ml (interquartile range [IQR]: 5); and median number of LNs removed was 6 (IQR: 8). A total of 3,698 (57%), 2,064 (32%), and 508 (8%) patients had ≥ 6, ≥ 10, and ≥ 20 LNs removed, respectively. Patients with more LNs removed were older, had a higher prostate specific antigen level, had higher clinical and pathologic T stage, and had higher RP Gleason score (all P<0.002). Within a median follow-up of 21 (IQR: 16) months, more LNs removed was associated with an increased risk of BCR (continuous: P = 0.021; categorical: P = 0.014). In multivariable analyses that adjusted for the effects of standard clinicopathologic factors, none of the nodal stratifications predicted BCR.CONCLUSIONS: The number of LNs did not have any prognostic significance in our contemporary cohort of patients with LN-negative prostate cancer. This suggests that the risk of missed clinically significant micrometastasis may be minimal in patients currently treated with RP and having a lower LN yield.",
author = "Kluth, {Luis A} and Evanguelos Xylinas and Malte Rieken and Chun, {Felix K-H} and Harun Fajkovic and Andreas Becker and Karakiewicz, {Pierre I} and Niccolo Passoni and Michael Herman and Yair Lotan and Christian Seitz and Paul Schramek and Mesut Remzi and Wolfgang Loidl and Bertrand Guillonneau and Morgan Roupr{\^e}t and Alberto Briganti and Scherr, {Douglas S} and Markus Graefen and Tewari, {Ashutosh K} and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2014 Elsevier Inc. All rights reserved.",
year = "2014",
month = jan,
day = "1",
doi = "10.1016/j.urolonc.2013.06.013",
language = "English",
volume = "32",
pages = "47.e1--8",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?

AU - Kluth, Luis A

AU - Xylinas, Evanguelos

AU - Rieken, Malte

AU - Chun, Felix K-H

AU - Fajkovic, Harun

AU - Becker, Andreas

AU - Karakiewicz, Pierre I

AU - Passoni, Niccolo

AU - Herman, Michael

AU - Lotan, Yair

AU - Seitz, Christian

AU - Schramek, Paul

AU - Remzi, Mesut

AU - Loidl, Wolfgang

AU - Guillonneau, Bertrand

AU - Rouprêt, Morgan

AU - Briganti, Alberto

AU - Scherr, Douglas S

AU - Graefen, Markus

AU - Tewari, Ashutosh K

AU - Shariat, Shahrokh F

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - OBJECTIVES: To determine if the number of lymph nodes (LNs) removed is an independent predictor of biochemical recurrence (BCR) in patients without LN metastases undergoing radical prostatectomy (RP).MATERIAL AND METHODS: Retrospective analysis of 7,310 patients treated at 7 centers with RP and pelvic LN dissection for clinically localized prostate cancer between 2000 and 2011. Patients with LN metastases (n = 398) and other reasons (stated later in the article) (n = 372) were excluded, which left 6,540 patients for the final analyses.RESULTS: Overall, median biopsy and RP Gleason score were both 7; median prostate specific antigen level was 6 ng/ml (interquartile range [IQR]: 5); and median number of LNs removed was 6 (IQR: 8). A total of 3,698 (57%), 2,064 (32%), and 508 (8%) patients had ≥ 6, ≥ 10, and ≥ 20 LNs removed, respectively. Patients with more LNs removed were older, had a higher prostate specific antigen level, had higher clinical and pathologic T stage, and had higher RP Gleason score (all P<0.002). Within a median follow-up of 21 (IQR: 16) months, more LNs removed was associated with an increased risk of BCR (continuous: P = 0.021; categorical: P = 0.014). In multivariable analyses that adjusted for the effects of standard clinicopathologic factors, none of the nodal stratifications predicted BCR.CONCLUSIONS: The number of LNs did not have any prognostic significance in our contemporary cohort of patients with LN-negative prostate cancer. This suggests that the risk of missed clinically significant micrometastasis may be minimal in patients currently treated with RP and having a lower LN yield.

AB - OBJECTIVES: To determine if the number of lymph nodes (LNs) removed is an independent predictor of biochemical recurrence (BCR) in patients without LN metastases undergoing radical prostatectomy (RP).MATERIAL AND METHODS: Retrospective analysis of 7,310 patients treated at 7 centers with RP and pelvic LN dissection for clinically localized prostate cancer between 2000 and 2011. Patients with LN metastases (n = 398) and other reasons (stated later in the article) (n = 372) were excluded, which left 6,540 patients for the final analyses.RESULTS: Overall, median biopsy and RP Gleason score were both 7; median prostate specific antigen level was 6 ng/ml (interquartile range [IQR]: 5); and median number of LNs removed was 6 (IQR: 8). A total of 3,698 (57%), 2,064 (32%), and 508 (8%) patients had ≥ 6, ≥ 10, and ≥ 20 LNs removed, respectively. Patients with more LNs removed were older, had a higher prostate specific antigen level, had higher clinical and pathologic T stage, and had higher RP Gleason score (all P<0.002). Within a median follow-up of 21 (IQR: 16) months, more LNs removed was associated with an increased risk of BCR (continuous: P = 0.021; categorical: P = 0.014). In multivariable analyses that adjusted for the effects of standard clinicopathologic factors, none of the nodal stratifications predicted BCR.CONCLUSIONS: The number of LNs did not have any prognostic significance in our contemporary cohort of patients with LN-negative prostate cancer. This suggests that the risk of missed clinically significant micrometastasis may be minimal in patients currently treated with RP and having a lower LN yield.

U2 - 10.1016/j.urolonc.2013.06.013

DO - 10.1016/j.urolonc.2013.06.013

M3 - SCORING: Journal article

C2 - 24055425

VL - 32

SP - 47.e1-8

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 1

ER -